A new gene-therapy technique, which entered early-stage clinical trials last week, may bring relief to cancer patients who suffer from chronic, untreatable pain. By delivering the gene for an opiate-like chemical directly to affected nerves, the treatment may circumvent the debilitating side effects normally associated with opiate drugs.
“This is a breakthrough study,” says Talal Khan, director of the Chronic and Interventional Pain Clinic at the University of Kansas Medical Center. “It’s the first gene-therapeutic trial for the management of pain.” Khan is not involved in the trial.
The new technique, developed by clinical neurologist David Fink and his colleagues at the University of Michigan, uses a crippled version of herpes simplex virus (HSV)–the virus responsible for cold sores–to deliver a therapeutic gene to affected nerves. This is also the first clinical trial that uses HSV to shuttle a foreign gene into the body.
HSV’s natural behavior makes it an ideal delivery vehicle, says Fink. It infects sensory neurons near the skin and travels to a group of cells near the spinal cord, but no farther, allowing the researchers to precisely target the therapy to those neurons involved in sensing pain. To administer the treatment, a doctor simply injects the virus into the skin wherever the pain occurs.
HSV also avoids what has been a troubling side effect of gene therapy: viral genes inserting themselves into the host’s genome. In a French trial of gene therapy for severe combined immunodeficiency, for instance, several children died when the therapeutic gene inserted itself into a cancer-related gene and caused leukemia. HSV merely ferries its genes to the nucleus, where they remain indefinitely, separate from the host’s genome. Unlike the naturally occurring virus, which can periodically reactivate itself and cause symptom flare-ups, the virus used for therapy is incapable of replicating.
Along with its own genes, the HSV vector is engineered to carry the gene for an opiate-like peptide called enkephalin. Enkephalin is involved in the body’s own pain-fighting response, binding to the same receptors as opiate drugs but far more effectively. Because it degrades quickly, enkephalin isn’t normally a candidate for treating pain. But by administering the gene encoding the peptide rather than the peptide itself, gene therapy can provide a continuously replenished supply.
The clinical trial will target cancer patients with localized pain for whom conventional painkillers have failed, either because the maximum dose was ineffective or because the side effects were incapacitating. Opiate drugs, which act on opiate receptors all over the body, generate a slew of side effects, including drowsiness, confusion, constipation, and respiratory depression. Patients often find these side effects more troublesome than their initial pain, says Fink. “They say, ‘I’d rather be awake with the pain than asleep with your medicine,’” he says.
The highly localized nature of the new treatment may help. “By expressing the natural peptide in only the area of the nervous system that’s responsible for transmitting the pain sensation,” says Fink, “we can block the pain without having those side effects.”
The technique has proved safe and effective in rodents, and Fink anticipates that these results will translate well to human patients. For the clinical trial, the enkephalin gene has been paired with a molecular switch that will deactivate it after a few weeks, in case any adverse reactions occur. Fink’s group has also developed switches that can continue to churn out enkephalin for months or even years.
While the University of Michigan study, sponsored by the Swedish biotech company Diamyd Medical, is the first to enter clinical trials, several other groups have been developing related gene therapies for treating chronic pain. In January, researchers at Mount Sinai School of Medicine announced that by injecting a virus carrying an opioid gene directly into spinal fluid, they successfully treated chronic pain in rats. Compared with that approach, the HSV-based therapy is far less invasive: the former is akin to a spinal tap, the latter to a flu shot.
HSV’s benefits may also pose a limitation, however. Many cancer patients experience pain throughout the body, not just at the site of the tumor. In those cases, localized relief is not enough. “This type of approach is not suited for pain all over the body,” says Fink.
Nonetheless, Fink believes that gene therapy will open up an entirely new way to approach chronic pain. “We understand a lot about how pain is perceived and how it works in the nervous system,” he says, “but we haven’t made tremendous progress on finding new ways to treat pain.”
Khan agrees that gene therapy can offer fresh treatment possibilities where old tactics have failed. “I see so many people who experience these chronic unremitting pains,” he says. “With the current tools that we have, our hands are really tied.”
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.